Zevra Therapeutics Files 8-K on Asset Disposition & Financials
Ticker: ZVRA · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, disposition, financial-condition, operations
TL;DR
ZEVRA filed an 8-K detailing asset deals and financials as of April 1, 2025.
AI Summary
On April 1, 2025, Zevra Therapeutics, Inc. reported on the completion of an acquisition or disposition of assets, as well as its results of operations and financial condition. The filing also included other events and financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on Zevra Therapeutics' asset transactions and financial performance, offering insights into the company's current operational status and strategic direction.
Risk Assessment
Risk Level: medium — The filing concerns asset disposition and financial results, which can indicate significant strategic shifts or performance issues for the company.
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 001-36913 (company_id) — Commission File Number
- 20-5894398 (company_id) — IRS Employer Identification No.
- 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (address) — Business Address
- April 1, 2025 (date) — Date of Earliest Event Reported
FAQ
What specific assets were acquired or disposed of by Zevra Therapeutics on or around April 1, 2025?
The filing indicates the completion of an acquisition or disposition of assets, but the specific details of the assets involved are not provided in the summary information.
What are the key highlights of Zevra Therapeutics' results of operations and financial condition as reported in this 8-K?
The filing states that results of operations and financial condition are being reported, but the specific financial details are not included in the provided text.
Were there any other significant events reported by Zevra Therapeutics on April 1, 2025, beyond asset transactions and financial reporting?
Yes, the filing explicitly mentions 'Other Events' as a category being reported on, in addition to asset disposition and financial condition.
What is the significance of Zevra Therapeutics previously being known as KemPharm, Inc.?
Zevra Therapeutics was formerly known as KemPharm, Inc., with name changes recorded on May 30, 2013, and May 7, 2008, indicating a rebranding or restructuring.
Where is Zevra Therapeutics, Inc. incorporated and what is its primary business sector?
Zevra Therapeutics, Inc. is incorporated in Delaware and operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding ZEVRA THERAPEUTICS, INC. (ZVRA).